MedWatch

ALK increases sales in Q2, but operating result decreases

Wednesday morning, allergy company ALK presented the full report for the year's second quarter. The central figures were known ahead of time, since the company upgraded its guidance on Monday.

Photo: ALK / PR

Wednesday morning, pharmaceutical company ALK shed light on the last unknown figures in the company's Q2 report. Since the firm published the main figures for the quarter on Monday, there were no great surprises.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs